Hippocampal volume correlates with attenuated negative psychotic symptoms irrespective of antidepressant medication

Raffaele Bernasconi\textsuperscript{a,1}, Renata Smieszkova\textsuperscript{a,1}, André Schmidt\textsuperscript{a,b}, Fabienne Harrisberger\textsuperscript{a}, Nora Maria Raschle\textsuperscript{a}, Claudia Lenz\textsuperscript{a}, Anna Walter\textsuperscript{a}, Andor Simon\textsuperscript{a}, Anita Rieber-Rössler\textsuperscript{a}, Ernst-Wilhelm Radue\textsuperscript{c}, Undine E. Lang\textsuperscript{a}, Paolo Fusar-Poli\textsuperscript{b,1}, Stefan J. Borgwardt\textsuperscript{b,1,c,}\textsuperscript{*}

\textsuperscript{a}Department of Psychiatry (UPK), Wilhelm Klein-Strasse 27, Basel, Switzerland
\textsuperscript{b}Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UK
\textsuperscript{c}Medical Image Analysis Centre, University Hospital, Basel, Switzerland

A R T I C L E   I N F O

Article history:
Received 13 March 2015
Received in revised form 23 April 2015
Accepted 25 April 2015
Available online 29 April 2015

Keywords:
Structural MRI
Antidepressant medication
Hippocampus
Precuneus
Negative psychotic symptoms

A B S T R A C T

Background: Individuals with at-risk mental state for psychosis (ARMS) often suffer from depressive and anxiety symptoms, which are clinically similar to the negative symptomatology described for psychosis. Thus, many ARMS individuals are already being treated with antidepressant medication.

Objectives: To investigate clinical and structural differences between psychosis high-risk individuals with or without antidepressants.

Methods: We compared ARMS individuals currently receiving antidepressants (ARMS-AD; n = 18), ARMS individuals not receiving antidepressants (ARMS-nonAD; n = 31) and healthy subjects (HC; n = 24), in terms of brain structure abnormalities, using voxel-based morphometry. We also performed region of interest analysis for the hippocampus, anterior cingulate cortex, amygdala and precuneus.

Results: The ARMS-AD had higher ‘depression’ and lower ‘motor hyperactivity’ scores than the ARMS-nonAD. Compared to HC, there was significantly less GMV in the middle frontal gyrus in the whole ARMS cohort and in the superior frontal gyrus in the ARMS-AD subgroup. Compared to ARMS-nonAD, the ARMS-AD group showed more gray matter volume (GMV) in the left superior parietal lobe, but less GMV in the left hippocampus and the right precuneus. We found a significant negative correlation between attenuated negative symptoms and hippocampal volume in the whole ARMS cohort.

Conclusion: Reduced GMV in the hippocampus and precuneus is associated with short-term antidepressant medication and more severe depressive symptoms. Hippocampal volume is further negatively correlated with attenuated negative psychotic symptoms. Longitudinal studies are needed to distinguish whether hippocampal volume deficits in the ARMS are related to attenuated negative psychotic symptoms or to antidepressant action.

© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

The clinical high-risk state of psychosis (at-risk mental state, hereafter ARMS) is defined by attenuated positive psychotic symptoms, genetic liability and functional deterioration or brief and self-remitting psychotic symptoms (Fusar-Poli et al., 2013; Yung et al., 1998). However, affective symptoms, including depressive and anxiety symptoms, are also highly prevalent in these individuals (Salokangas et al., 2012). A recent meta-analysis, conducted in 1683 high-risk subjects, confirmed that the baseline prevalence of comorbid depressive and anxiety disorder is 41% and 15%, respectively (Fusar-Poli et al., 2014a). Depressive and anxiety symptoms can precede the onset of attenuated positive psychotic symptoms (Fusar-Poli et al., 2013). Some studies indicate that co-occurrence of depressive disorders can predict subsequent transition to psychosis in ARMS individuals (Salokangas et al., 2012). However, other studies have not confirmed this finding (Fusar-Poli et al., 2014a). Additionally, a large study on 3349 twins suggests an association between depressive and/or anxiety symptoms and psychosis-like traits (schizotypy) and emphasizes a major role for genetics, especially as regards positive symptoms (Macare et al., 2012). The comorbidity of psychotic and depressive disorders in the ARMS population is associated with specific psychopathological features at the time of the presentation to high risk services and with low functional level (Fusar-Poli et al., 2013). Because of these problems, clinical high-risk individuals...
often receive antidepressant medication (e.g. 42% of ARMS individuals in our previous study (Smieskova et al., 2012a)).

Negative psychotic symptoms are a major source of disability in the psychosis spectrum and are refractory to any effective treatment (Fusar-Poli et al., 2014b). Negative symptoms group into two factors, one involving diminished expression of affect and alogia and the second involving avolition, including anhedonia and asociality (Fusar-Poli et al., 2014b). Antidepressants may have a potential benefit for ARMS individuals, as they may target their negative attenuated psychotic symptoms (Cornblatt et al., 2007; Fusar-Poli et al., 2007). These studies indicate that antidepressant treatments in ARMS individuals can impact their longitudinal outcomes. However, it is not clear if these improvements are associated with underlying neurobiological changes (Wood et al., 2011).

Neuroimaging studies using magnetic resonance imaging (MRI) have indicated that ARMS showed brain alterations in the prefrontal (Borgwardt et al., 2006; Borgwardt et al., 2008; Koutsouleris et al., 2009; Mechelli et al., 2011; Wood et al., 2010), cingulate (Fornito et al., 2008; Koutsouleris et al., 2009), superior (Takahashi et al., 2009; Takahashi et al., 2010) and medial temporal (Borgwardt et al., 2007b; Tognin et al., 2014), insular (Smieskova et al., 2010) and cerebellar regions when compared to healthy controls. Furthermore, ARMS individuals with subsequent transition to psychosis showed volumetric reductions in the prefrontal, insular and cingulate cortex compared to those without transition (Smieskova et al., 2010).

Similar alterations were found in depressive disorders. Reductions in gray matter volume (GMV) in the anterior cingulate gyrus, hippocampus, amygdala (Koolschijn et al., 2009) and prefrontal cortex (Lorenzetti et al., 2009) were associated with major depression. The only available study directly testing the effect of comorbid depressive disorders on the neurobiology of ARMS uncovered a significant impact on the anterior cingulate region (Modinos et al., 2014). On the other hand, long-term antidepressant medication can be neuroprotective and some studies have linked the use of antidepressants to an increase in hippocampal volume in patients with major depressive disorder (Amico et al., 2011; Mablykhn et al., 2010). It has been shown that antidepressants increase hippocampal neurogenesis (Anacker et al., 2011). Thus, both affective symptoms (Baynes et al., 2000) and antidepressant medication (Kraus et al., 2014) are known to impact brain structure.

In the present study, we addressed for the first time the effect of antidepressant treatment and attenuated negative psychotic symptoms on the neurobiology of ARMS. Firstly, we hypothesized that ARMS individuals without current antidepressant treatment (ARMS-nonAD) would manifest more severe attenuated negative symptoms than ARMS subjects currently receiving antidepressants (ARMS-AD). Secondly, we hypothesized that ARMS-AD individuals would have increased GMV in regions associated with depressive symptoms and/or antidepressant medication (hippocampus, anterior cingulate gyrus, amygdala and precuneus) compared to the ARMS-nonAD individuals. Thirdly, we hypothesized that the volumetric abnormalities in gray matter between ARMS-AD and ARMS-nonAD would be associated with attenuated negative symptoms.

2. Materials and methods

2.1. Subjects

MRI data were collected within the framework of a research program on the early detection of psychosis. The subjects were recruited in our specialized clinic for the early detection of psychosis (FEPSY) at the Psychiatric Outpatient Department, Psychiatric University Clinics Basel, Switzerland (Riecher-Rössler et al., 2006).

The entire group of ARMS individuals (n = 49) conforms to Yung’s criteria (Yung et al., 1998) and overlaps with previously published data (Borgwardt et al., 2007a; Borgwardt et al., 2007b; Smieskova et al., 2012a; Smieskova et al., 2012b). All the ARMS individuals were antipsychotic-free and were assessed prior to the neuroimaging session. ARMS inclusion required one or more of the following:

(a) attenuated psychotic symptoms that do not reach full psychosis threshold
(b) brief limited intermittent psychotic symptoms (lasting less than a week with spontaneous remission)
(c) a first degree relative with a psychotic disorder plus at least two indicators of a clinical change, such as a marked decline in social or occupational functioning.

We assessed the subjects using the Basel Screening Instrument for Psychosis (BSIP) (Riecher-Rössler et al., 2008), the Brief Psychiatric Rating Scale (BPRS) (Lukoff et al., 1986), the Scale for the Assessment of Negative Symptoms (SANS) (Andreasen, 1989) and the Global Assessment of Functioning (GAF) (Endicott et al., 1976). Attenuated negative psychotic symptom severity was investigated with the cluster ‘negative symptoms’, calculated from the BPRS as a sum of blunted affect, emotional withdrawal, and motor retardation (BPRS16, BPRS17 and BPRS18) (Fusar-Poli et al., 2014b; Velligan et al., 2005). Additionally, we calculated ‘mood disturbance’ BPRS cluster as a sum of anxiety, depression, suicidality and guilt (BPRS02, BPRS03, BPRS04 and BPRS05) (Thomas et al., 2004), as well as depression (BPRS03) and motor retardation (BPRS18) scores alone. We used these scores for stepwise regression analysis with backward elimination.

In a second step, we divided the ARMS individuals into two subgroups, based on whether they were currently being treated with antidepressants (ARMS-AD, n = 18) or not (ARMS-nonAD, n = 31) (Table 1). Antidepressant medication within the AD subgroup included: fluoxetine (SSRI; n = 2), escitalopram (SSRI; n = 5), sertraline (SSRI; n = 1), mirtazapine [NASSA (noradrenergic and specific serotonergic antidepressant); n = 4], venlafaxine [SSNRI (selective serotonin-norepinephrine reuptake inhibitor)], n = 2], duloxetine (SSNRi; n = 2), fluoxetine plus trazodone (SSRI, SARI (serotonin antagonist and reuptake inhibitor); n = 1) and St. John’s Wort (n = 1). Antidepressant therapy had a mean duration of 50 ± 47 days (range 4–170 days). In order to exclude possible biases through antipsychotic therapy, we confirmed that all individuals were antipsychotic-free. In addition, current and previous psychotropic medication, alcohol, nicotine, cannabis, and other illegal drug consumption were assessed using a semi-structured interview, as adapted from the Drug and Alcohol Assessment Schedule of the Early Psychosis Prevention and Intervention Centre (EPPIIC).

Participants were excluded from the study if they presented with a history of previous psychotic disorder, psychotic symptomatology secondary to an organic disorder, substance abuse, affective psychosis, borderline personality disorder, age under 18 or over 40, inadequate knowledge of the German language or IQ less than 70 (assessed by multiple-choice vocabulary intelligence test) (Lehl et al., 1995).

Healthy controls (n = 24) were from the same geographical area as the other groups (Table 1). All participants provided written informed consent. The study was approved by the local ethics committee.

2.2. Magnetic resonance imaging acquisition

For structural imaging, a whole brain 3D T1-weighted MPRAGE (magnetization prepared rapid acquisition gradient) sequence was applied using a 3 T magnetic resonance imaging scanner (Magnetom Verio, Siemens Healthcare, Erlangen, Germany) and a 12-channel radio frequency head coil. The acquisition was based on a sagittal matrix of 256 × 256 × 176 and 1 × 1 × 1 mm3 isotropic spatial resolution, with an inversion time of 1000 ms, repetition time of 2 s, echo time of 3.4 ms, flip angle of 8° and bandwidth of 200 Hz/pixel. All images were reviewed by trained neuroradiologists for radiological abnormalities.
2.3. Image analysis

Structural MRI data were analyzed using the voxel-based morphometry toolbox (VBM8, http://dbm.neuro.uni-jena.de/vbm8/), implemented within SPM8 (Wellcome Department of Cognitive Neurology, London, UK) and running on Matlab 7.11 (MathWorks, USA). All Tr-weighted images were first checked for scanner artifacts and anatomical abnormalities. Images were then segmented into gray matter, white matter and cerebrospinal fluid using the adaptive maximum a posteriori technique for registration and additional registration in MNI space was uncontrolled using an isotropic 8 mm full-width-at-half-maximum (FWHM) Gaussian kernel (Shen and Sterr, 2013).

Group differences were explored using a one-way ANOVA. Since our groups differed significantly in gender and age, we introduced these two variables as additional covariates of interest. Group comparisons included ARMS-AD versus ARMS-nonAD versus healthy controls. Brain region labeling was achieved using the Harvard–Oxford structural atlas (http://fmrib.ox.ac.uk/fsl/fslwiki/Atlases) (Desikan et al., 2006)), incorporated within the FMRIIB Software Library (FSL).

Table 1

Demographic and clinical data.

| Characteristic            | ARMS-AD [n = 18] | ARMS-nonAD [n = 31] | HC [n = 24] | Statistic | Post hoc |
|---------------------------|------------------|---------------------|-------------|-----------|----------|
| Gender M/F                | 14/4             | 24/7                | 10/14       | 2.43      | 0.078    |
| Mean age (SD)             | 24.9 (5.0)       | 23.9 (4.9)          | 27.6 (4.6)  | 4.140     | 0.000    |
| Handedness (left)         | 1 (5.6%)         | 2 (6.5%)            | 2 (8.3%)    | 0.138     | 0.933    |
| Years of education (SD)   | 14.11 (3.45)     | 11.05 (2.59)        | 16.00 (2.80) | 7.123     | 0.654    |
| BPRS total score (SD)     | 41.56 (8.00)     | 39.04 (9.37)        | 24.54 (11.0) | 36.971    | 0.000    |
| BPRS mood disturbance (SD)| 11.22 (3.34)     | 9.35 (3.64)         | 4.50 (0.98) | 30.746    | 0.000    |
| BPRS negative symptoms (SD)| 6.33 (2.43)  | 5.36 (2.78)         | 3.00 (0.00) | 13.699    | 0.000    |
| BPRS depression (SD)      | 4.17 (1.15)      | 3.23 (1.33)         | 1.13 (0.34) | 47.456    | 0.000    |
| BPRS motor hyperactivity  | 1.00 (0.00)      | 1.48 (0.89)         | 1.00 (0.00) | 5.856     | 0.000    |
| SANS total score (SD)     | 22.00 (11.55)    | 17.88 (14.26)       | 0.00 (0.00) | 25.721    | 0.000    |
| GAF (SD)                  | 62.11 (10.92)    | 66.0 (12.38)        | 88.08 (4.15) | 45.236    | 0.000    |
| Cigarettes smoked per day (SD)| 12.83 (8.92) | 5.31 (8.32)         | 3.25 (6.52) | 8.105     | 0.000    |
| Current cannabis use      | 11               | 8                   | 4           | 10.226    | 0.000    |
| Current alcohol use       | 3/10             | 7/21/3              | 1/2/1       | 8.125     | 0.000    |
| Days on antidepressants (SD)| 50 (47)        | None                | None        | 8.087     | 0.000    |
| Range days                | 4–170            |                     |             |           |         |

Abbreviations: ARMS, at-risk mental state individuals; ARMS-AD, ARMS with antidepressants; ARMS-nonAD, ARMS without antidepressants; BPRS, Brief Psychiatric Rating Scale; ‘BPRS depression’, BPRS3; ‘BPRS motor hyperactivity’, BPRS23; ‘BPRS mood disturbance’, as a sum of anxiety, depression, suicidality and guilt (BPRS02, BPRS03, BPRS04 and BPRS05); ‘BPRS negative symptoms’ as a sum of blunted affect, emotional withdrawal, and motor retardation (BPRS16, BPRS17 and BPRS18); GAF, Global Assessment of Functioning; HC, healthy controls; SANS, Scale for the Assessment of Negative Symptoms.

* Bonferroni correction (at p = 0.05) was calculated for post hoc analysis in SPSS 22.0. Only post hoc results between ARMS-AD and ARMS-nonAD groups are presented.

** Significant results in post hoc analysis between ARMS-AD and ARMS-nonAD.

Statistical significance was assessed at a cluster level using a threshold of p < 0.005 uncorrected (cluster-forming threshold); statistical inference was then made at p < 0.05, adjusted to provide a family-wise error (FWE) correction at the peak and cluster levels.

2.4. ROI analysis

On the basis of the previous evidence, we defined 4 specific regions of interest (ROIs) to test for differences in GMV between our two ARMS groups: the bilateral hippocampus, (associated with greater risk of depressive disorder; Amico et al., 2011; Vasconcelos et al., 2011), the anterior cingulate gyrus (reported to be reduced during ongoing depression; Amico et al., 2011; Koolschijn et al., 2009) and in co-morbid depression in ARMS (Modinos et al., 2014); the amygdala (inconsistent changes in depression; Amico et al., 2011; Koolschijn et al., 2009) and the precuneus (associated with increased gray matter density after short antidepressant application in HC; Kraus et al., 2014).

All the regions were individually defined using the Wake Forest University PickAtlas Toolbox (http://fmri.wfubmc.edu/software/PickAtlas). For each region, a small volume correction was conducted using a 5 mm radius for the hippocampus (Amico et al., 2011; Vasconcelos et al., 2011) and amygdala or a 10 mm radius for the precuneus and anterior cingulate cortex (ACC) (Abutalebi et al., 2012; Amico et al., 2011).

Mean gray matter volume indices were extracted from these regions using the Rex Toolbox (http://web.mit.edu/swg/software.htm) implemented in Matlab 7.11. The analysis was performed on region of interest basis, with no conjunction mask, no scaling and extraction of the mean within the predefined ROI. The extracted values were used for a
stepwise backward regression analysis (see Supplementary table). Only corrected family-wise error values were taken into consideration, in order to avoid a type I error.

2.5. Statistical analysis of clinical variables

Clinical and socio-demographic differences were assessed using one-way ANOVA and χ²-test. For post hoc analysis, the Bonferroni correction was conducted. In addition, a stepwise regression analysis with backward elimination was applied, to restrict correlating variables. We included the BPRS total score and SANS total score; as well as the BPRS clusters for ‘negative symptoms’ as a sum of blunted affect, emotional withdrawal, and motor retardation (BPRS16, BPRS17 and BPRS18); and ‘mood disturbance’ as a sum of anxiety, depression, suicidality and guilt (BPRSO2, BPRSO3, BPRSO4 and BPRSO5); and the single scores ‘depression’ (BPRS 3) and ‘motor hyperactivity’ (BPRS 23) (see Supplementary table). We applied outlier detection using Cook’s Distance Test and no subject had to be excluded from regression analysis. Still, we excluded one ARMS-nonAD individual due to missing data in the BPRS 16, 17, and 18 necessary for calculating the cluster ‘negative symptoms’. We then performed a correlation with our significant clinical parameters from the stepwise regression. From the regions of interest with significant differences between ARMS-AD and ARMS-nonAD (hippocampus and precuneus), we extracted the volumes and used them in our in correlation calculations. The data were normally distributed and we performed a series of two-tailed Pearson’s correlation analyses with statistical threshold set at p < 0.05. All analyses were performed using the Statistical Package for the Social Science (SPSS, Version 22).

3. Results

3.1. Clinical and demographic characteristics

The ARMS-AD, ARMS-nonAD and HC showed significant differences in age at MRI scan (p = 0.02), gender (p = 0.01), years of education (p = 0.002), smoking (p = 0.001), and cannabis (p = 0.006); but no differences in alcohol consumption or handedness. Post hoc analysis showed that smoking (p = 0.006) and cannabis consumption (p = 0.014) were significantly more common in the ARMS-nonAD group than in the ARMS-nonAD group (Table 1). The differences in alcohol consumption were not significant. Moreover, the antidepressants may take weeks or longer to take effect after dosage (Penn and Tracy, 2012). The duration of antidepressant treatment varied from 4 to 170 days and thus the therapy in the ARMS-AD group differs from 4 to 170 days and thus the therapy in the ARMS-AD group (p = 0.029) than the ARMS-nonAD (Table 1). The test of our a priori defined contrast in attenuated negative symptoms (BPRS cluster for ‘negative symptoms’) between ARMS-nonAD and ARMS-AD found no significant difference (p = 0.220).

3.2. Whole brain analysis

Compared to the HC, there was significantly less GMV in the middle frontal gyrus in the whole ARMS cohort, and in the superior frontal gyrus in the ARMS-AD group (puncorr. < 0.05, Table 2).

The ARMS-nonAD group showed reduced GMV in the left superior parietal lobe compared with the ARMS-AD group (puncorr. < 0.05, Table 2).

3.3. Region of interest analyses

The ARMS-AD group had less GMV in the left hippocampus (Fig. 1) and right precuneus than the ARMS-nonAD (pFWE-corr. < 0.05 after small volume correction, Table 2). However, these results did not survive correction for multiple comparisons (p = 0.0125). No significant differences were found for the ACC and amygdala.

3.4. Correlation between ROI volumes and clinical parameters

We found a negative correlation between the hippocampal volume and the BPRS ‘negative symptoms’ cluster, both in ARMS subjects (r = −0.314, p = 0.030, Fig. 2) and in all our subjects, including the HC (r = −0.293, p = 0.013).

There was no significant correlation between the BPRS ‘negative symptoms’ and the precuneus volume.

4. Discussion

In the present study, we addressed for the first time the effect on psychosis of antidepressant treatment and attenuated psychotic symptoms in ARMS individuals. Firstly, we have found no evidence for our first hypothesis, that ARMS individuals suffer more pronounced attenuated negative psychotic symptoms if they have not been treated with antidepressants. We found that ARMS-AD individuals had a higher depression score, lower motor hyperactivity and smoked more cigarettes and marijuana than the ARMS-nonAD individuals. The antidepressants that ARMS-AD individuals were receiving differed in their mode of action – some inhibited the reuptake of serotonin and/or noradrenaline, while others enhanced the release of these monoamines (Andrade and Rao, 2010). Moreover, the antidepressants may take weeks or longer to take effect after dosage (Penn and Tracy, 2012). The duration of antidepressant therapy in the ARMS-AD group varies from 4 to 170 days and thus the

| Contrast | Region | p value | KE/radius | z value | x | y | z |
|----------|--------|---------|-----------|---------|---|---|---|
| 1. Whole brain analysis | ARMS < HC | Middle frontal gyrus | 0.035 | 790 | 3.59 | −33 | 57 | 16 |
| | ARMS-AD < HC | Superior frontal gyrus | 0.028 | 874 | 3.98 | −33 | 57 | 18 |
| | ARMS-nonAD < ARMS-AD | Left superior parietal lobe | 0.023 | 944 | 4.33 | −32 | −40 | 45 |
| 2. Region of interest | ARMS-AD < ARMS-nonAD | Left hippocampus | 0.029 | 5 mm | 2.86 | −18 | −19 | 17 |
| | ARMS-AD < ARMS-nonAD | Right precuneus | 0.042 | 10 mm | 3.23 | 10 | −78 | 51 |

Table 2

Between group differences in gray matter volume.

The data presented here are from ANOVA of 3 included groups (ARMS-AD, ARMS-nonAD, HC) at a threshold of p < 0.005 uncorrected across the whole brain. There were no significant differences in the following contrasts: ARMS > HC, ARMS-AD > HC, ARMS-nonAD vs. HC, and ARMS-nonAD > ARMS-AD.

Abbreviations: ARMS, at-risk mental state; ARMS-AD, ARMS subjects currently receiving antidepressants; ARMS-nonAD, ARMS individuals without current antidepressant medication; HC, healthy controls; KE, voxels per cluster; x y z, coordinates according to the Montreal Neurological Institute.

Abbreviations: ARMS — at-risk mental state; ARMS-AD — ARMS with antidepressants; ARMS-nonAD — ARMS without antidepressants; KE — voxels per cluster.

*p < 0.0125 required.
observed effect could be indicative of both the predominant depressive and/or attenuated negative psychotic symptoms or of the already developed antidepressant effect of the medication. Hence, we cannot clearly distinguish the extent to which each of the two components contributes to the current clinical state.

Secondly, we did not find increased GMV in the regions associated with depressive symptoms in those ARMS who were receiving antidepressants, compared to those without this medication. Thus we could not confirm our second hypothesis, but found GMV deficits in the hippocampus and precuneus only in the ARMS individuals currently receiving antidepressant medication.

Our third hypothesis is related to the volumetric abnormalities in ARMS and their association with the attenuated negative symptoms; we confirmed this relationship in the hippocampus. We found a clear negative correlation between the bilateral hippocampal volume and attenuated negative symptoms in all ARMS individuals. This corresponds to studies linking the hippocampus with psychosis (Jun et al., 2012). Previous studies similarly either found negative correlations between the left hippocampal volume and negative symptoms in schizophrenics (Rajarethinam et al., 2001), or at least a strong trend in this direction (Brambilla et al., 2013). These findings underline the role of the hippocampus in the pathophysiology of schizophrenia and suggest specific associations between individual structures and both the positive and negative symptoms of the illness (Kühn et al., 2012; Rajarethinam et al., 2001). Thus, our findings support the importance of hippocampal structures as a region of interest in the early stage of psychosis (Benetti et al., 2009; Fusar-Poli et al., 2012; Walter et al., 2012).

Our ROI analysis demonstrated smaller GMV in the left hippocampus in the ARMS-AD group than in the ARMS-nonAD group. The hippocampus is involved in various psychiatric conditions, including major depression and psychosis (Videbech and Ravnkilde, 2004; Walter et al., 2012). Three meta-analyses have confirmed significant reductions in the hippocampal volume in depression (Campbell et al., 2004; Cole et al., 2011; Videbech and Ravnkilde, 2004). Furthermore, the total number of depressive episodes was significantly correlated to the reduction in the right hippocampal volume (Videbech and Ravnkilde, 2004). The left-hemispheric deficits in hippocampal volume may reflect brain degeneration, as a consequence of chronic stress (Schmidt and Duman, 2010). Recent data on antipsychotic-free ARMS have confirmed that vulnerability to psychosis may be associated with a significant decrease in hippocampal volume (Fusar-Poli et al., 2012; Wood et al., 2010).

In the right precuneus, we found less GMV in the ARMS-AD group than in the ARMS-nonAD group. This is consistent with Grieve et al. (Grieve et al., 2013), who found significant reductions in the precuneus volumes, along with several other structural changes in depression. However, the direction of the effect is controversial. For example, a
positive association was described between the volume of the precuneus and the severity of depression (Kroes et al., 2011). It is well established that intrusive imagery and increased self-focus, common in patients suffering from depression, are regularly associated with higher depression scores (Kroes et al., 2011). Since the precuneus is involved in visuospatial processing, imagery and self-related processing (Kjaer et al., 2002; Wenderoth et al., 2005), depression could in principle enhance its GMV.

We acknowledge the limitations of a cross-sectional design, which precludes studying clinical and structural abnormalities within the same group of ARMS before and after antidepressant medication. In order to decide whether brain volumetric deficits are related to distinct depressive symptoms or to the antidepressant effect, longitudinal study designs are needed. Secondly, other confounders, such as nicotine and cannabis consumption, may have influenced our findings (higher consumption in ARMS-AD individuals). Furthermore, the ARMS-nonAD group shows more motor hyperactivity than the ARMS-AD group. This could result from the early effect of the antidepressant medication or from the sedative effect of cannabis or nicotine self-medication, which was higher in the ARMS-AD group (Warburton, 1985). Cigarette use may serve as an instrument to alleviate depressive symptoms, although the role of cannabis consumption is unclear. We can only speculate that the attenuated negative symptoms may drive cannabis consumption, although this abuse may exacerbate the positive symptoms observed (Gill et al., 2013). We are also aware that not all negative symptoms are of hippocampal origin. In addition, the prescribed antidepressant drugs have different affinities to various synaptic receptors and therefore their effects on macroscopic structures and neurogenesis may vary and also be associated with other brain regions. Likewise, differences in the duration of antidepressant therapy may affect their impact on brain structure. Finally, relatively small sample groups are included, which reduces the statistical power to detect any significant effects.

5. Conclusion

Hippocampal volume was negatively associated with attenuated negative psychotic symptoms in ARMS individuals. Surprisingly, ARMS individuals without antidepressant medication did not suffer more pronounced attenuated negative psychotic symptoms. The short-term antidepressant medication in this study is more likely to be an indicator of a more serious depressed state than to have a direct effect on attenuated negative psychotic symptoms. These findings emphasize the importance of comorbidity issues, especially in the context of depressive and attenuated negative psychotic symptoms in clinical high-risk individuals and their functional outcomes.

Supplementary material for this article can be found online at http://dx.doi.org/10.1016/j.nicl.2015.04.016.

References

Abutalebi, J., Della Rosa, P.A., Green, D.W., Hernandez, M., Scifo, P., Keim, R., Cappa, S.F., Costa, A., 2012. Bilingualism tunes the anterior cingulate cortex for conflict monitoring. Cereb. Cortex 22 (9), 2076–2086. http://dx.doi.org/10.1093/cercor/bhs272.

Amico, F., Meisenzahl, E., Koutsouleris, N., Reiser, M., Müller, H.J., Frot, T., 2011. Structural MRI correlates for vulnerability and resilience to major depressive disorder. J. Psychiatry Neurosci. 36 (1), 15–22. http://dx.doi.org/10.1503/jpn.090182.

Anacker, C., Zunszain, P.A., Carvalho, L.A., Pariante, C.M., 2011. The glucocorticoid receptor: pivot of depression and of antidepressant treatment? Psychoneuroendocrinology 36 (3), 415–425. http://dx.doi.org/10.1016/j.psyneuen.2010.03.009.

Andrade, C., Rao, N.S., 2010. How antidepressant drugs act: a primer on neuroplasticity as the eventual mediator of antidepressant efficacy. Indian J. Psychiatry 52 (4), 378–386. http://dx.doi.org/10.4103/0019-5545.743182.

Andreasen, N.C., 1989. The Scale for the Assessment of Negative Symptoms (SANS): conceptual and theoretical foundations. Br. J. Psychiatry Suppl. 49–58.

Ashburner, J., 2007. A fast diffeomorphic image registration algorithm. Neuroimage 38 (1), 95–113. http://dx.doi.org/10.1016/j.neuroimage.2007.07.007.

Baynes, D., Mulholland, C., Cooper, S.J., Montgomery, R.C., Macfury, G., Lynch, G., Kelly, C., King, D.J., 2000. Depressive symptoms in stable chronic schizophrenia: prevalence and relationship to psychopathology and treatment. Schizophr. Res. 45 (1–2), 47–56. http://dx.doi.org/10.1016/S0920-9964(00)00205-4.

Benetti, S., Mechelli, A., Picchioni, M., Breeze, M., Williams, S., McGuire, P., 2009. Functional integration between the posterior hippocampus and prefrontal cortex is impaired in both first episode schizophrenia and the at risk mental state. Brain 132 (9), 2426–2436. http://dx.doi.org/10.1093/brain/awp981.

Borgwardt, S.J., Radue, E-W., Götz, K., Aston, J., Drew, M., Gschwendtner, U., Haller, S., Pflüger, M., Stieglitz, R-D., McGuire, P.K., Riecher-Rössler, A., 2006. Radiological findings in individuals at high risk of psychosis. J. Neurol. Neurosurg. Psychiatry 77 (2), 229–233. http://dx.doi.org/10.1136/jnnp.2005.069690.

Borgwardt, S.J., McGuire, P.K., Aston, J., Berger, C., Dazzan, P., Gschwendtner, U., Pflüger, M., D’Souza, M., Radue, E-W., Riecher-Rössler, A., 2007a. Structural brain abnormalities in individuals with an at-risk mental state who later develop psychosis. Br. J. Psychiatry Suppl. 51, s68–s75. http://dx.doi.org/10.1192/bjp.191.51.s6918055941.
Tognin, S., Riecher-Rössler, A., Meisenzahl, E.M., Wood, S.J., Hutton, C., Borgwardt, S.J., Koutsouleris, N., Yung, A.R., Allen, P., Phillips, L.J., McGorry, P.D., Vally, I., Velakoulis, D., Nelson, B., Woolley, J., Pantelis, C., McGuire, P., Mechelli, A., 2014. Reduced parahippocampal cortical thickness in subjects at ultra-high risk for psychosis. Psychol. Med. 44 (3), 489–498. http://dx.doi.org/10.1017/S00332917130009823659473.

Vasconcelos, L.de G., Jackowski, A.P., Oliveira, M.O., Flor, Y.M., Bueno, O.F., Brucki, S.M., 2011. Voxel-based morphometry findings in Alzheimer’s disease: neuropsychiatric symptoms and disability correlations — preliminary results. Clinics (Sao Paulo) 66 (6), 1045–1050. http://dx.doi.org/10.1590/S1807-5932201100060002121808873.

Velligan, D., Prihoda, T., Dennehy, E., Biggs, M., Shores-Wilson, K., Crismon, M.L., Rush, A.J., Miller, A., Suppes, T., Trivedi, M., Kasher, T.M., Witte, B., Toprac, M., Carmody, T., Chiles, J., Shon, S., 2005. Brief Psychiatric Rating Scale expanded version: how do new items affect factor structure? Psychiatry Res. 135 (3), 217–228. http://dx.doi.org/10.1016/j.psychres.2005.05.00115993949.

Videbech, P., Ravnkilde, B., 2004. Hippocampal volume and depression: a meta-analysis of MRI studies. Am. J. Psychiatry 161 (11), 1957–1966. http://dx.doi.org/10.1176/appi.ajp.161.11.195715514393.

Warburton, D.M., 1985. Nicotine and the smoker. Rev. Environ. Health 5 (4), 343–3903916378.

Wenderoth, N., Debaere, F., Sunaert, S., Swinnen, S.P., 2005. The role of anterior cingulate cortex and precuneus in the coordination of motor behaviour. Eur. J. Neurosci. 22 (1), 235–246. http://dx.doi.org/10.1111/j.1460-9568.2005.04176.x16029213.

Wood, S.J., Kennedy, D., Phillips, L.J., Seal, M.L., Yücel, M., Nelson, B., Yung, A.R., Jackson, G., McGorry, P.D., Velakoulis, D., Pantelis, C., 2010. Hippocampal pathology in individuals at ultra-high risk for psychosis: a multi-modal magnetic resonance study. Neuroimage 52 (1), 62–68. http://dx.doi.org/10.1016/j.neuroimage.2010.04.01220399273.

Wood, S.J., Yung, A.R., McGorry, P.D., Pantelis, C., 2011. Neuroimaging and treatment evidence for clinical staging in psychotic disorders: from the at-risk mental state to chronic schizophrenia. Biol. Psychiatry 70 (7), 619–625. http://dx.doi.org/10.1016/j.biopsych.2011.05.03421762875.

Yung, A.R., Phillips, L.J., McGorry, P.D., McFarlane, C.A., Francey, S., Harrigan, S., Patton, G.C., Jackson, H.J., 1998. Prediction of psychosis. A step towards indicated prevention of schizophrenia. Br. J. Psychiatry Suppl. 172 (33), 14–200764121.